The goal of this clinical trial is to learn if nitazoxanide (NTZ) can treat Cryptosporidium infection in children age 6-12 months. The main questions it aims to answer are:
* Does NTZ treatment of diarrheal Cryptosporidium infection lower the number of days of diarrhea?
* Does NTZ treatment of diarrheal and non-diarrheal Cryptosporidium infection lower the number of days that parasites can be found in the stool?
Researchers will compare NTZ to a placebo (a look-alike substance that contains no drug) to see if NTZ works to treat Cryptosporidium.
Participants will:
* Take NTZ or placebo for 3 days
* Receive regular visits from field research assistants
* Provide blood and urine samples

Start Date12 Jan 2026

Sponsor / Collaborator

Johns Hopkins Bloomberg School of Public Health

[+1]

NCT07110441

/ CompletedPhase 1

A Phase 1, Open Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy Subjects

A Phase 1, Open-Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy Subjects

Start Date26 Aug 2025

Sponsor / Collaborator

Genfit SA

ChiCTR2500108033

/ Not yet recruitingNot ApplicableIIT

Tolizumab (anti-IL-6) in combination with nitazoxanide (anti-Wnt/β-catenin) in the treatment of recurrent or surgical residual enamel cell-type craniopharyngiomas

Start Date01 Aug 2025

Sponsor / Collaborator-

100 Clinical Results associated with Nitazoxanide

100 Translational Medicine associated with Nitazoxanide

100 Patents (Medical) associated with Nitazoxanide

1,281

Literatures (Medical) associated with Nitazoxanide

31 Dec 2026·PHARMACEUTICAL BIOLOGY

Kaempferol activity on Cryptosporidium parvum infection in an experimentally infected immunocompromised mouse model: In silico and in vivo investigations

Article

Author: El-Wakil, Eman S. ; Alsulami, Muslimah N. ; Azab, Haytham ; Wakid, Majed H.

CONTEXT:

No vaccine or effective therapy for cryptosporidiosis currently exists, except for nitazoxanide (NTZ), which has limited effectiveness in immunocompromised hosts. Kaempferol (KPF), a naturally occurring flavonoid, has various pharmacological effects and promising antiparasitic properties.

OBJECTIVE:

The current work aimed to examine the impact of KPF compared with NTZ on Cryptosporidium parvum (C. parvum) using both in silico molecular docking and in vivo studies with an experimentally infected immunocompromised mouse model.

MATERIALS AND METHODS:

The present study utilized KPF and NTZ as multi-target ligands to predict, determine, and evaluate their in silico target-interacted forms, thereby demonstrating their therapeutic properties against C. parvum. Mice were immunosuppressed and divided into six groups: DEXA, Model, KPF as prophylaxis, treatment with KPF, NTZ, and a combination of KPF and NTZ. Treatment efficacy was assessed through parasitological, histopathological examination, and immunohistochemical analysis of intestinal tissues using NLRP3 protein.

RESULTS:

The in silico findings supported the use of KPF and NTZ as inhibitors of C. parvum growth by blocking the action of C. parvum choline and pyruvate kinases. The in vivo study demonstrated that KPF exhibits anti-cryptosporidial efficacy, particularly when combined with NTZ. The KPF+NTZ had the best results, as evidenced by a significant decrease (p < 0.001) in oocyst shedding of 83%, improved intestinal histological damage, and inhibition of the NLRP3 inflammasome pathway.

DISCUSSION AND CONCLUSION:

KPF demonstrated the potential to mitigate the consequences of cryptosporidiosis and serve as an adjuvant agent to NTZ by reducing the oocyst burden, alleviating intestinal inflammation, and facilitating mucosal repair.

01 Feb 2026·LIFE SCIENCES

Modulating MiR-350/Akt/mTOR/beclin1 signaling by nitazoxanide ameliorates bleomycin-induced pulmonary fibrosis in a wistar rat model

Article

Author: Elbaz, Eman M ; Abdelmonem, Maha ; Abdel Rahman, Amina A S ; Shawky, Yara

AIMS:

Pulmonary fibrosis (PF) is a destructive, inflammatory intersectional lung disease that has lethal consequences. Autophagy, a cellular homeostasis sustaining system, has shown a vital function in PF progression. Nitazoxanide (NTZ) is a broad-spectrum antiprotozoal agent that exhibits anti-inflammatory, antiviral, and anti-fibrotic properties. This study explores the potential therapeutic effect of NTZ on bleomycin (BLM)-induced PF in rats and studies its impact on autophagy pathways.

MATERIALS AND METHODS:

Four groups of adult male Wistar rats: the control group, BLM group (intratracheal single dose of 5 mg/kg), BLM + NTZ (200 mg/kg/day, p.o., for 28 days) group, and BLM + wortmannin (WM) (15 μg/kg/day, i.v., for 28 days) group, where WM was used to validate the role of PI3K/Akt/mTOR signaling pathway in PF.

KEY FINDINGS:

BLM administration promoted extensive degenerative changes and distortion of lung architecture that were reversed by NTZ. BLM upregulated the miR-350, PI3K/Akt/mTOR pathway, transforming growth factor-β1 (TGF-β1), and Smad3 while reducing autophagy-related proteins; beclin1 and LC3B, and the anti-inflammatory interleukin-37 (IL-37) relative to the control group. BLM induced tissue inflammation and apoptosis, and increased TNF-α, IL-6, and caspase-3 relative to the control group. NTZ significantly alleviated BLM-induced collagen fiber deposition and PF, suppressed miR-350/Akt/mTOR signaling, TGF-β1, IL-6, TNF-α, caspase-3 expressions, upregulated IL-37, and elevated autophagy-related proteins relative to the BLM group.

SIGNIFICANCE:

This study demonstrates, for the first time, the potential role of miR-350 in PF, and reveals a potential therapeutic role for NTZ in ameliorating BLM-induced PF, presumably by modifying the miR-350/Akt/mTOR/beclin1 signaling.

01 Feb 2026·CANCER LETTERS

Corrigendum to “Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis” [Cancer Letters 633 (2025) 217990]

Author: Ghosh, Chandrayee ; Shen, Min ; Kebebew, Electron ; Zhang, Ya-Qin ; Hu, Jiangnan ; Alamaw, Eden Demissie ; Gunda, Viswanath ; Zhang, Lisa ; Tabdili, Yasmine ; Khaket, Tejinder Pal ; Yang, Zhongyue ; Boufraqech, Myriem ; Kassu, Rodas

News (Medical) associated with Nitazoxanide

06 Jan 2026

·ir.genfit.com

GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N

Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluation Compelling anti-inflammatory activity of G1090N was evidenced through functional ex vivo assays on blood samples from study participants and cirrhotic donors, showing inhibition of pro-inflammatory pathway Findings provide a solid foundation for advancing G1090N into Phase 2 proof-of-concept studies across the ACLF continuum Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 6, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that G1090N – a small molecule and the Company’s lead investigational drug candidate for Acute-On-Chronic Liver Failure (ACLF) – demonstrated a favorable Phase 1 safety profile, and a strong anti-inflammatory activity in ex-vivo studies. Dr. Jacqueline O’Leary, MD at the UT Southwestern Medical Center, Dallas, TX (USA), commented: “The safety profile observed in Phase 1 and the consistent biological activity evidenced in ex vivo assays represent a meaningful step in development. These findings position G1090N as a promising candidate for patients with acute decompensation and for patients with ACLF, a life-threatening condition with no approved therapies and significant unmet medical need. We are eager to see more patient data as the program moves forward, to confirm G1090N’s safety and strengthen the case for its activity in patients with organ failure.” Phase 1 The Phase 1, open-label trial assessed the safety, tolerability and pharmacokinetics (PK) of G1090N in healthy volunteers following a Single Ascending Dose administration (SAD) phase, and a Multiple Ascending Dose administration (MAD) phase. 13 healthy volunteers were enrolled in each segment, with a total of 76 participants. G1090N’s safety profile observed in healthy volunteers supports continued evaluation. Ex vivo studiesGENFIT evaluated the modulation of inflammation-related signaling pathways in ex vivo pharmacodynamic and proof-of-efficacy assays: G1090N demonstrated robust biological activity in peripheral blood mononuclear cells (PBMC) assays from healthy volunteers using blood samples from Phase 1 study participants, on LPS-induced IL-6 and TNFα cytokines production, with up to 76% statistically significant inhibition (p<0.0001); The bioactive metabolite of G1090N confirmed its anti-inflammatory potential on ex vivo assays performed on blood collected from cirrhotic donors. These findings indicate that G1090N: Displays strong anti-inflammatory activity at the doses tested in the first-in-human study Effectively engages its target mechanism of action in circulating immune cells Modulates key pathways driving systemic inflammation, a major contributor to acute decompensated cirrhosis with or without ACLF. Next stepsThese results support further clinical development of G1090N. GENFIT will engage with regulatory authorities, including the U.S. Food and Drug Administration, to determine the best approach for progressing to Phase 2 proof-of-concept in inflammatory conditions such as ACLF where systemic immune dysregulation is a critical driver of disease progression. END ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT's expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.1 Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com FORWARD LOOKING STATEMENTSThis press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements about the future development of G1090N, including plans to advance into Phase 2 proof-of-concept studies, anticipated regulatory interactions, potential therapeutic benefits in ACLF and related conditions, and the expected progression of GENFIT’s research and development programs. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.com) and the AMF's website (bdif.amf-france.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC, including the Half-Year Business and Financial Report at June 30, 2025, or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACTS GENFIT | Investors Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 | jean-christophe.marcoux@genfit.com GENFIT | Media Bruno Arabian – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.frStephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo® . Attachment GENFIT : Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N

Clinical ResultPhase 1

22 Sep 2025

·www.fiercebiotech.com

Genfit ends liver failure program after seeing adverse event in phase 2 trial

Genfit predicted that axing the development of VS-01 in acute-on-chronic liver failure will substantially reduce its spending. \n Genfit has stopped development of VS-01 in acute-on-chronic liver failure (ACLF) after a patient suffered a serious adverse event in a phase 2 trial. The French drugmaker acquired VS-01 when it bought Versantis for 40 million Swiss francs ($50 million) in 2022. Genfit subsequently made ACLF its top priority, advancing a phase 2 trial of VS-01 in the setting while expanding its pipeline to include six programs. After making changes to address slow enrollment, the biotech was aiming to publish phase 2 data on VS-01 in ACLF this year.Genfit disclosed a change of plan after the U.S. stock market closed Friday. The company has stopped development of VS-01 in ACLF in response to a case of peritonitis, a condition characterized by inflammation of the tissue that lines the abdomen.The independent data monitoring committee concluded the Unveil-IT study can continue, Genfit said, but it would require additional monitoring. Genfit opted against continuing the study with the suggested precautions after considering the target population’s clinical profile and the implications of the safety signal for the benefit-risk profile of VS-01 in ACLF. Genfit is stopping the phase 2 Unveil-IT trial and a proof-of-concept study, both of which were focused on ACLF. The biotech is continuing its preclinical evaluations of the asset in urea cycle disorder (UCD). Genfit noted differences between UCD and ACLF patients and drug administration setup, plus evidence of the effect of VS-01 on ammonia clearance, to explain its decision. The biotech will continue to develop four other assets in ACLF. Those candidates have different routes of administration and mechanisms of action than VS-01, suggesting they may be free from the safety signal, but are earlier in development. Genfit’s next data drop will cover safety results and early signs of efficacy from a study of G1090N in healthy volunteers. The biotech has scheduled the data release for late 2025. Genfit predicted that axing the development of VS-01 in ACLF will substantially reduce its spending. The biotech said it could use cash freed up by the discontinuation to extend its runway by at least one year, pushing the end beyond 2028, or to strike deals. Guggenheim analysts said in a note to investors that the company may have the strategic flexibility to pursue opportunities for additional early-stage ACLF assets.

Phase 2Acquisition

19 Mar 2025

·www.globenewswire.com

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the reference listed drug (RLD) Alinia®. "The market launch of Nitazoxanide Tablets, another niche limited competition product, underscores our purpose of ‘Serving Patients, Improving Lives’,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. "We share ANI’s commitment to providing affordable, high-quality medicines for the patients who depend on them and are pleased to partner on the launch of this limited competition product,” stated Dr. Jagadeesh Rangisetty, Chief Executive Officer of Biophore. U.S. annual sales for Nitazoxanide Tablets total approximately $36.1 million, based on December 2024 moving annual total (MAT) IQVIA data. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com. About Biophore India Pharmaceuticals Pvt. Ltd.Biophore, an established pharmaceutical company, is engaged in the development and manufacturing of niche, high quality pharmaceutical products for the generic industry. Since its inception in 2007, Biophore has emerged as a trusted partner for niche and complex products in the generic industry across US, Europe and other regulated markets. For more information, please visit our website, http://www.biophore.com/. Forward-Looking StatementsThis press release contains not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “continue,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “shall,” “would” other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of our approved products, including Cortrophin Gel, ILUVIEN and YUTIQ, to achieve commercialization at levels of market acceptance that will continue to allow us to achieve profitability; our ability to complete or achieve any, or all of the intended benefits of acquisitions and investments, including the acquisition of Alimera, in a timely manner or at all; the limitation of our cash flow as a result of the indebtedness and liabilities incurred from the recent acquisition of Alimera; the risks that our acquisitions and investments, including the recent acquisition of Alimera, could disrupt our business and harm our financial position and operating results; delays and disruptions in production of our approved products, increased costs and potential loss of revenues if we need to change suppliers due to the limited number of suppliers for our raw materials, active pharmaceutical ingredients, expedients, and other materials; delays and disruptions in production of our approved products as a result of our reliance on single source third party contract manufacturing supply for certain of our key products, including Cortrophin Gel, ILUVIEN and YUTIQ; delays or failure in obtaining and maintaining approvals by the FDA of the products we sell; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies, and the focus of the current U.S. presidential administration, including among other things, drug recalls, regulatory approvals, facility inspections and potential enforcement actions; risks that we may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of our products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the ability of our manufacturing partners to meet our product demands and timelines; the impact of changes or fluctuations in exchange rates; our ability to develop, license or acquire, and commercialize new products; our obligations in agreements under which we license, develop or commercialize rights to products or technology from third parties and our ability to maintain such licenses; the level of competition we face and the legal, regulatory and/or legislative strategies employed by our competitors to prevent or delay competition from generic alternatives to branded products; our ability to protect our intellectual property rights; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the impact of any litigation to which we are, or may become, a party; our ability, and that of our suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; our ability to maintain the services of our key executives and other personnel; and general business and economic conditions, such as inflationary pressures, geopolitical conditions including but not limited to the conflict between Russia and the Ukraine, the conflict in the Middle East, conflicts related to the attacks on cargo ships in the Red Sea, and the effects and duration of outbreaks of public health emergencies. More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: ANI Pharmaceuticals, Inc.

Drug Approval

100 Deals associated with Nitazoxanide

External Link

KEGG	Wiki	ATC	Drug Bank
D02486	Nitazoxanide	P01AX11	DB00507

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cryptosporidiosis	United States	Romark, L.C.	22 Nov 2002
Diarrhea	United States	Romark, L.C.	22 Nov 2002
Giardiasis	United States	Romark, L.C.	22 Nov 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Post Acute COVID 19 Syndrome	Phase 3	United States	Romark, L.C.	13 May 2020
COVID-19	Phase 3	United States	Romark, L.C.	12 May 2020
Viral respiratory infection	Phase 3	United States	Romark, L.C.	12 May 2020
Common Cold	Phase 3	United States	Romark, L.C.	11 Sep 2018
Enterovirus Infections	Phase 3	United States	Romark, L.C.	11 Sep 2018
Rhinovirus infection	Phase 3	United States	Romark, L.C.	11 Sep 2018
Influenza B virus infection	Phase 3	United States	Romark, L.C.	01 Mar 2013
Influenza B virus infection	Phase 3	Australia	Romark, L.C.	01 Mar 2013
Influenza B virus infection	Phase 3	Belgium	Romark, L.C.	01 Mar 2013
Influenza B virus infection	Phase 3	Canada	Romark, L.C.	01 Mar 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT07110441 (Company_Website) Manual	Phase 1	-	76	G1090N	uvokccnaey(rjwuokmzqr) = favorable safety and tolerability profile, supporting further clinical evaluation dkihaqigmg (kdjouqcanw ) View more	Positive	06 Jan 2026
NCT04532931 (CTgov)	Phase 2	COVID-19	192	SOC+Paracetamol (SOC) (Arm A)	tmifhfiwft = uocwpwfptf apwrbljszo (ylshmgimrf, mirtdijpdd - nncubunwea) View more	-	28 Jul 2025
				Artesunate+Amodiaquine (Arm B)	tmifhfiwft = ospioyunwk apwrbljszo (ylshmgimrf, vxihopoktc - sgyowtmyfo) View more
NCT04489381 (CTgov)	Phase 3	Rhinovirus infection \| Common Cold \| Enterovirus Infections	214	Vitamin Super B-Complex+Nitazoxanide (Nitazoxanide)	lwhyvduwjv(lsgiukrdyk) = pghoyydhqi bqpdrcxamo (wfgaodnafx, zuifnhmjys - oedaindvnc) View more	-	17 Oct 2024
				Placebo (Placebo)	lwhyvduwjv(lsgiukrdyk) = fgmjizfhsw bqpdrcxamo (wfgaodnafx, ltmuofylbp - alynovpnog) View more
UEGW2024	Not Applicable	Infectious Diseases	-	Levofloxacin, nitazoxanide, doxycycline, and lansoprazole (LNDL)	lscbxzysjk(kxvcmovvus) = abqpdtcpwj fwdgbetkgn (kymnglruwr, 75.73 - 91.27)	-	13 Oct 2024
				Moxifloxacin, nitazoxanide, doxycycline, and lansoprazole (MNDL)	lscbxzysjk(kxvcmovvus) = jdjpsvrcth fwdgbetkgn (kymnglruwr, 73.57 - 90.01)
NCT04343248 (CTgov)	Phase 3	COVID-19 \| Viral respiratory infection	190	Vitamin Super B-Complex+Nitazoxanide (Nitazoxanide)	gqkplftzxf = eiatomnsst bfhntlxcme (yhkfffjncr, aasrzzdqpv - pnvbrhwxun) View more	-	08 Jul 2024
				Placebo (Placebo)	gqkplftzxf = tlylhtsosc bfhntlxcme (yhkfffjncr, rnnjzestez - cvqsutfwwy) View more
NCT04359680 (CTgov)	Phase 3	COVID-19 \| Post Acute COVID 19 Syndrome \| Viral respiratory infection	1,407	Vitamin Super B-Complex+Nitazoxanide (Nitazoxanide)	bgxqvflhnu = rjgfkqzbnp yiubiymhfd (lzwkhecebt, tcqbzpoxir - vutfcvguzy) View more	-	26 Jun 2024
				Placebo (Placebo)	bgxqvflhnu = tamxjkkhpy yiubiymhfd (lzwkhecebt, adjwptgalr - kjqwkgwtrz) View more
NCT04486313 (CTgov)	Phase 3	COVID-19	935	Vitamin Super B-Complex+Nitazoxanide (Nitazoxanide)	rmwgngoftu(wzdrwhvenw) = wzkyrxpwrx tmckjjmeuo (yuwnadrugy, ovvrxrczzt - cnlhroanyt) View more	-	29 Mar 2024
				Placebo (Placebo)	rmwgngoftu(wzdrwhvenw) = rocqekxwun tmckjjmeuo (yuwnadrugy, whxexmxtkd - litlrwmokf) View more
NCT03905655 (CTgov)	Phase 2	Hepatitis B, Chronic	51	Placebo Oral Tablet (Group 1)	blggpcbiwt(kouwfrcgre) = ensxooyfzx euuqikxodj (vstbiyvznv, 0.13) View more	-	07 Nov 2023
				Placebo Oral Tablet+Nitazoxanide (Group 2)	blggpcbiwt(kouwfrcgre) = nmyaovxata euuqikxodj (vstbiyvznv, 0.90) View more
NCT03395405 (CTgov)	Phase 2	Gastroenteritis	31	Nitazoxanide (Nitazoxanide (500 mg))	cbzvwegwiz(mhwtsbqjhl) = kqptrpkaan tobxbqarlf (tuoguxawiy, qdwogqfdmo - xzeguspghp) View more	-	24 Oct 2022
				placebo (Placebo)	cbzvwegwiz(mhwtsbqjhl) = chdfehnagf tobxbqarlf (tuoguxawiy, cxtrwycfbv - iznjepvwtt) View more
NCT03656068 (CTgov)	Phase 2	Fibrosis, Liver \| Metabolic Dysfunction Associated Steatohepatitis \| Compensated cirrhosis	21	NTZ	zjfdtyvxij = xfxostitmd honadxpsan (ueqxdmihim, hjxhwcslrq - krtiaoamqs) View more	-	30 Jun 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nitazoxanide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation